Polymeric binder and high molecular weight polymer antifouling compositions
AssigneeThe University of British Columbia
InventorsHossein Yazdani-Ahmadabadi, Kai Yu, Dirk Lange, Jayachandran Kizhakkedathu
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions including polymeric binder or a salt thereof, high molecular weight polymer, pharmaceutically active agent and a low molecular weight cross-linking agent, methods for using the compositions to coat a substrate, and methods for making the compositions. Alternatively, the composition may include a polymeric binder or a salt thereof, high molecular weight polymer and a pharmaceutically active agent. In particular, the substrate may form part of an apparatus on which it would be beneficial to limit biofouling and/or protein binding.
Claims21
A composition, the composition comprising:
- (a) a polymeric binder or a salt thereof, wherein a monomer of the polymeric binder has the following structure:
- wherein,
- D is selected from
- (b) a high molecular weight polymer selected from a poly(N,N-dimethylacrylamide) (PDMA) polymer having a number average molecular weight of ≥200 kDa and a (2-ethyl-2-oxazoline) (POXZ) polymer having a number average molecular weight of ≥200 kDa;
- (c) a pharmaceutically active agent;
- and
- (d) a low molecular weight cross-linking agent, wherein the cross linking agent is selected from polyethylenimine (PEI) and polyvinyl pyrrolidone (PVP), having a number average molecular weight of between about 0.7 kDa and about 4.0 kDa.
A composition, the composition comprising:
- (a) dopamine;
- (b) PDMA having a number average molecular weight of 800 kDa;
- (c) AgNO3;
- and
- (d) PEI having a number average molecular weight of between about 0.7 kDa and about 4.0 kDa;
- or
- (a) dopamine;
- (b) PDMA having a number average molecular weight of between about 800 kDa and about 925 kDa;
- (c) docetaxel;
- and
- (d) PEI having a number average molecular weight of between about 0.7 kDa and about 4.0 kDa;
- or
- (a) dopamine;
- (b) PDMA having a number average molecular weight of between about 800 kDa and about 925 kDa;
- (c) paclitaxel;
- and
- (d) PEI having a number average molecular weight of between about 0.7 kDa and about 4.0 kDa.
A composition, the composition comprising:
- (a) a polymeric binder or a salt thereof, wherein a monomer of the polymeric binder has the following structure:
- wherein,
- D is selected from
- (b) a high molecular weight polymer selected from a N,N-dimethylacrylamide (PDMA) polymer having a number average molecular weight of ≥200 kDa and a (2-ethyl-2-oxazoline) (POXZ) polymer having a number average molecular weight of ≥200 kDa;
- (c) a pharmaceutically active agent;
- and
- (d) a low molecular weight cross-linking agent, wherein the cross-linking agent is selected from polyethylenimine (PEI) and polyvinyl pyrrolidone (PVP), having a number average molecular weight of between about 0.30 kDa and about 25 kDa.
Dependencies are inferred from the claim text.